{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:10:04Z","timestamp":1756663804425,"version":"3.44.0"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023551","name":"Cystic Fibrosis Ireland","doi-asserted-by":"crossref","award":["national charity"],"award-info":[{"award-number":["national charity"]}],"id":[{"id":"10.13039\/501100023551","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European commission for CFMATTERS","award":["603038"],"award-info":[{"award-number":["603038"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,4,14]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Previous studies showed that the combination of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector and potentiator, lumacaftor\u2013ivacaftor (LUMA\u2013IVA) provides meaningful clinical benefits in patients with cystic fibrosis who are homozygous for the Phe508del <jats:italic>CFTR<\/jats:italic> mutation. However, little is known about the effect of LUMA\u2013IVA on Proinflammatory Cytokines (PICs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the impact of LUMA\u2013IVA <jats:italic>CFTR<\/jats:italic> modulation on circulatory and airway cytokines before and after 12 months of LUMA\u2013IVA treatment in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed both plasma and sputum PICs, as well as standard clinical outcomes including Forced Expiratory Volume in one second (FEV<jats:sub>1<\/jats:sub>) %predicted, Body Mass Index (BMI), sweat chloride and pulmonary exacerbations at baseline and prospectively for one year post commencement of LUMA\u2013IVA in 44 patients with cystic fibrosis aged 16 years and older homozygous for the Phe508del <jats:italic>CFTR<\/jats:italic> mutation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Significant reduction in plasma cytokines including interleukin (IL)-8 (p&lt;0.05), tumour necrosis factor (TNF)-\u03b1 (p&lt;0.001), IL-1\u00df (p&lt;0.001) levels were observed while plasma IL-6 showed no significant change (p=0.599) post-LUMA\u2013IVA therapy. Significant reduction in sputum IL-6 (p&lt;0.05), IL-8 (p&lt;0.01), IL-1\u00df (p&lt;0.001) and TNF-\u03b1 (p&lt;0.001) levels were observed after LUMA\u2013IVA therapy. No significant change was noted in anti-inflammatory cytokine IL-10 levels in both plasma and sputum (p=0.305) and (p=0.585) respectively. Clinically significant improvements in FEV<jats:sub>1<\/jats:sub> %predicted (mean+3.38%, p=0.002), BMI (mean+0.8 kg\/m<jats:sup>2<\/jats:sup>, p&lt;0.001), sweat chloride (mean \u221219 mmol\/L, p&lt;0.001), as well as reduction in intravenous antibiotics usage (mean \u22120.73, p&lt;0.001) and hospitalisation (mean \u22120.38, p=0.002) were observed after initiation of LUMA\u2013IVA therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This real-world study demonstrates that LUMA\u2013IVA has significant and sustained beneficial effects on both circulatory and airway inflammation. Our findings suggest that LUMA\u2013IVA may improve inflammatory responses, which could potentially contribute to improved standard clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001590","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T11:29:34Z","timestamp":1683026974000},"page":"e001590","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor\u2013ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis\u2014an observational study"],"prefix":"10.1136","volume":"10","author":[{"given":"Parniya","family":"Arooj","sequence":"first","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"},{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"},{"name":"Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David V","family":"Morrissy","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"},{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"},{"name":"Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"},{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Vagg","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"},{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairead","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Fleming","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Daly","sequence":"additional","affiliation":[{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Eustace","sequence":"additional","affiliation":[{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond M","family":"Murphy","sequence":"additional","affiliation":[{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"},{"name":"Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B J","family":"Plant","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre (3CF), Cork University Hospital, Cork, Ireland"},{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"},{"name":"Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"2025083110565885000_10.1.e001590.1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025083110565885000_10.1.e001590.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1510466"},{"key":"2025083110565885000_10.1.e001590.3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025083110565885000_10.1.e001590.4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (progress): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025083110565885000_10.1.e001590.5","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-022-00624-z","article-title":"Real life evaluation of the multi-organ effects of lumacaftor\/ivacaftor on F508del homozygous cystic fibrosis patients","volume":"23","author":"Yaacoby-Bianu","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025083110565885000_10.1.e001590.6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110565885000_10.1.e001590.7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S153719"},{"key":"2025083110565885000_10.1.e001590.8","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00156.2002"},{"key":"2025083110565885000_10.1.e001590.9","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.2.91"},{"key":"2025083110565885000_10.1.e001590.10","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9704086"},{"key":"2025083110565885000_10.1.e001590.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2025083110565885000_10.1.e001590.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.10.005"},{"key":"2025083110565885000_10.1.e001590.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404-0703OC"},{"key":"2025083110565885000_10.1.e001590.14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110565885000_10.1.e001590.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2025083110565885000_10.1.e001590.16","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05032-11"},{"key":"2025083110565885000_10.1.e001590.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.10.002"},{"key":"2025083110565885000_10.1.e001590.18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcf.2018.07.011","article-title":"Lumacaftor\/ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in fev1","volume":"18","author":"McColley","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2025083110565885000_10.1.e001590.19","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24129"},{"key":"2025083110565885000_10.1.e001590.20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cyto.2013.03.029","article-title":"Effects of treatment in the levels of circulating cytokines and growth factors in cystic fibrosis and dialyzed patients by multi-analytical determination with a biochip array platform","volume":"62","author":"Tirelli","year":"2013","journal-title":"Cytokine"},{"key":"2025083110565885000_10.1.e001590.21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199601)21:1<11::AID-PPUL2>3.0.CO;2-T"},{"key":"2025083110565885000_10.1.e001590.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(05)80263-X"},{"key":"2025083110565885000_10.1.e001590.23","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"Elife"},{"key":"2025083110565885000_10.1.e001590.24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of lumacaftor-ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in phe508del homozygous patients with cystic fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110565885000_10.1.e001590.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2008.11.007"},{"key":"2025083110565885000_10.1.e001590.26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125669"},{"key":"2025083110565885000_10.1.e001590.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022655","article-title":"Anti-Inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis","volume":"6","author":"Jouneau","year":"2011","journal-title":"PLoS One"},{"key":"2025083110565885000_10.1.e001590.28","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-12-3","article-title":"The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis","volume":"12","author":"Ngan","year":"2012","journal-title":"BMC Pulm Med"},{"key":"2025083110565885000_10.1.e001590.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2004.06.006"},{"key":"2025083110565885000_10.1.e001590.30","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020334","article-title":"Anti-infectives restore ORKAMBI\u00ae rescue of F508del-CFTR function in human bronchial epithelial cells infected with clinical strains of P. aeruginosa","volume":"10","author":"Laselva","year":"2020","journal-title":"Biomolecules"},{"key":"2025083110565885000_10.1.e001590.31","doi-asserted-by":"crossref","first-page":"L635","DOI":"10.1152\/ajplung.00198.2017","article-title":"Vx-809\/vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells","volume":"314","author":"Ruffin","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2025083110565885000_10.1.e001590.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209026","article-title":"Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor\/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation","volume":"13","author":"Pohl","year":"2018","journal-title":"PLoS ONE"},{"key":"2025083110565885000_10.1.e001590.33","doi-asserted-by":"publisher","DOI":"10.1042\/cs0850563"},{"key":"2025083110565885000_10.1.e001590.34","doi-asserted-by":"publisher","DOI":"10.1063\/1.341780"},{"key":"2025083110565885000_10.1.e001590.35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1164\/rccm.201710-1983OC","article-title":"Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in phe508del homozygous patients with cystic fibrosis","volume":"197","author":"Graeber","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110565885000_10.1.e001590.36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-Life safety and effectiveness of lumacaftor\u2013ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110565885000_10.1.e001590.37","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204532"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:57:09Z","timestamp":1756663029000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,2]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjresp-2022-001590"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001590","relation":{},"ISSN":["2052-4439"],"issn-type":[{"type":"electronic","value":"2052-4439"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}